Related Experiment Video
Updated: Aug 6, 2026
Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model
Published on: December 9, 2018
The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation
L A Ambrosio1, G Marchese, A Filippo
1Psychiatric Centre, Annunziata Hospital, Cosenza, Italy.
Abstract:
Mesoglycan is a preparation of natural glycosaminoglycans, containing mainly heparan sulphate and dermatan sulphate. A clinical trial was conducted to evaluate the efficacy and the tolerability of once-daily mesoglycan in 30 patients with clinical evidence of cerebrovascular insufficiency. Clinical effectiveness was assessed using psychometric and neurological scales: Sandoz Clinical Assessment for Geriatric Patients (SCAG); Parkside Behaviour Rating Scale Modified; Geriatric Depression Scale; and Anxiety Evaluation. Mesoglycan was given as a single oral once-daily dose of 100 mg for a period of 6 months. This treatment was shown to have positive effects on the cognitive and behavioural parameters evaluated. The effects on SCAG were already evident after 3 months' treatment and a significant improvement was observed after 6 months in those patients with a moderate to severe disease. During the treatment period only one patient suffered an adverse reaction attributed to the drug investigated.
Insights
Daily oral mesoglycan improved cognitive and behavioral function in patients with cerebrovascular insufficiency. This glycosaminoglycan preparation demonstrated good tolerability over a 6-month trial.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Cerebrovascular insufficiency impacts cognitive and behavioral functions.
- Glycosaminoglycans, like heparan and dermatan sulfate, are being investigated for therapeutic potential.
Purpose of the Study:
- To evaluate the efficacy and tolerability of daily oral mesoglycan in patients with cerebrovascular insufficiency.
Main Methods:
- A 6-month clinical trial involving 30 patients.
- Once-daily oral administration of 100 mg mesoglycan.
- Assessment using psychometric and neurological scales (SCAG, Parkside, GDS, Anxiety).
Main Results:
- Positive effects on cognitive and behavioral parameters were observed.
- Improvements in SCAG scores were evident by 3 months, with significant gains by 6 months in moderate to severe cases.
- Only one patient reported a drug-related adverse reaction, indicating good tolerability.
Conclusions:
- Once-daily oral mesoglycan is effective and well-tolerated for managing cerebrovascular insufficiency.
- The treatment shows promise in improving cognitive and behavioral deficits associated with the condition.
